地拉罗司疗效如何？

Deferasirox is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is used for patients with iron accumulation due to long-term blood transfusion (such as thalassemia or other rare anemias). It is suitable for children over two years old and adults. So, how effective is Deferasirox?

To evaluate the efficacy and safety of a new oral iron chelator, Deferasirox, in the treatment of iron overload in patients with β-thalassemia major (β-thalassaemia). 

Results: None of the 23 patients with severe β-thalassaemia used in the study group used iron chelators regularly before treatment, and their iron overload condition was severe [the average baseline value of serum ferritin was (5433.96±2873.90) μg/L].20 mg·kg-1·d-1 of Deferasirox can maintain the patient's iron overload in a balanced state, and there is no significant change in serum ferritin levels before and after treatment; with the extension of treatment time, the dosage increases, ≥30 mg·kg-1·d-1 deferasirox can bring patients' iron overload to a negative balance state, and the difference in serum ferritin levels before and after treatment is statistically significant (P<0.01). 

There were no serious adverse events of Deferasirox (Deferasirox) during the 3-year follow-up. Common adverse reactions were mild increases in liver transaminase and serum creatinine. All 23 patients were able to take the medication on time and successfully completed the clinical study, with no deaths. Conclusion As a new type of oral iron chelator, Deferasirox (Deferasirox) can significantly improve the iron overload status of patients, and its efficacy is related to treatment time and drug dosage. 

With its simple medication method, good safety and tolerability, Deferasirox can significantly improve the quality of life of patients and better meet the treatment needs of patients with iron overload.

Iron overload increases the risk of infection, endocrine system damage, vital organ dysfunction, AML transformation in MDS patients, and shortens survival. Iron chelators are currently the mainstream treatment for iron removal. Among them, Deferasirox is easy to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment.

The above is the content of (Enrig, Deferasirox) effects, I hope it can help you!